SCHEMBL420249

SCHEMBL420249

NNS(=O)(=O)c1cccc(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.53
PGR P06401 2/20 0.50
FLT1 P17948 1/20 0.50
FLT4 P35916 1/20 0.50
KDR P35968 1/20 0.50
BRD4 O60885 1/20 0.49
WDR5 P61964 1/20 0.49
HSD17B2 P37059 1/20 0.49
EDNRB P24530 2/20 0.48
EDNRA P25101 2/20 0.48
PKM P14618 1/20 0.47
KAT6A Q92794 2/20 0.47
MEN1 O00255 1/20 0.46
CASP6 P55212 1/20 0.46
GFER P55789 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
CTSL P07711 1/20 0.44
CTSK P43235 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148204 0.85 CA2 (0.54) PKMMEN1CASP6GFERKMT2A
SCHEMBL3531211 0.80 ATM (0.53) ATMPGRFLT1FLT4KDR
SCHEMBL2372604 0.80 ATM (0.53) ATMPGRFLT1FLT4KDR
SCHEMBL31689440 0.80 TNNI3K (0.60) ATMPGRFLT1FLT4KDR
SCHEMBL11962953 0.80 CA1 (0.59) ATMPGRFLT1FLT4KDR
SCHEMBL264637 0.80 TNNI3K (0.60) ATMPGRFLT1FLT4KDR
SCHEMBL138127 0.79 KMT2A (0.58) PKMMEN1CASP6GFERKMT2A
SCHEMBL11101389 0.79 PTGES2 (0.50) FLT1FLT4KDREDNRBEDNRA
SCHEMBL5991904 0.79 CYP1A2 (0.53) ATMFLT1FLT4KDRBRD4
SCHEMBL11406378 0.78 LMNA (0.63) PKMKAT6AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184582-A 4-Seleno-1-benzenesulfonyl pyrazole compound and electrochemical synthesis method and application thereof 延安大学 2024-06-14 CN disclosed
CN-117143072-A Preparation method and application of sulfonyl substituted naphtho [1,8-bc ] thiophene compound 扬州大学 2023-12-01 CN disclosed
CN-111978216-B Preparation method of beta-carbonyl sulfone compound 西南医科大学 2023-02-03 CN disclosed
CN-112920123-B 3-aryl-6-aralkyl-1, 4,5, 6-tetrahydropyrazines compound and preparation method and application thereof 江苏冠瑜生物科技有限公司 2022-09-16 CN disclosed
CN-112358424-B Preparation method of sulfinate compound 浙江工业大学 2022-06-21 CN disclosed
CN-112920123-A 3-aryl-6-aralkyl-1, 4,5, 6-tetrahydropyrazines compound and preparation method and application thereof 苏州大学 2021-06-08 CN disclosed
CN-111978216-A Preparation method of beta-carbonyl sulfone compound 西南医科大学 2020-11-24 CN disclosed
CN-109096158-B Preparation method of (E) -alkenyl sulfone compound 石家庄学院 2020-06-12 CN disclosed
CN-109096158-A A kind of preparation method of (E)-alkenyl sulfone compound 石家庄学院 2018-12-28 CN disclosed
US-9115065-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses Kineta, Inc. (US) 2015-08-25 US disclosed
US-8410149-B2 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses SIGA TECHNOLOGIES INC. (US) 2013-04-02 US disclosed
WO-2012060820-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2012-05-10 WO disclosed
US-20120022027-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES INC. (US) 2012-01-26 US disclosed
US-7994221-B2 Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses SIGA TECHNOLOGIES, INC. (US) 2011-08-09 US disclosed
US-20110118505-A1 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses SIGA TECHNOLOGIES INC. (US) 2011-05-19 US disclosed
US-20100256096-A1 Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses SIGA TECHNOLOGIES, INC. 2010-10-07 US disclosed
EP-2124921-A2 SULFONYL SEMICARBAZIDES, CARBONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2009-12-02 EP disclosed
WO-2008147474-A2 SULFONYL SEMICARBAZIDES, CARBONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2008-12-04 WO disclosed
EP-1827446-A2 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES SIGA TECHNOLOGIES, INC. (US) 2007-09-05 EP disclosed
WO-2006062898-A2 COMPOUNDS AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES SIGA TECHNOLOGIES, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118505-A1 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses SORD, GBA1, GK ATM 1505/4885PGR 4085/4885FLT1 3150/4885
US-20100256096-A1 Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses GBA1, SORD, GK ATM 1517/4885PGR 4047/4885FLT1 2698/4885
US-20120022027-A1 SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES GBA1, GK, GCK ATM 1694/4885PGR 4427/4885FLT1 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.